A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia.

MLA

Fadlyana, Eddy, et al. “A Phase III, Observer-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18–59 Years: An Interim Analysis in Indonesia.” Vaccine, vol. 39, no. 44, Oct. 2021, pp. 6520–28. EBSCOhost, https://doi.org/10.1016/j.vaccine.2021.09.052.

APA

Fadlyana, E., Rusmil, K., Tarigan, R., Rahmadi, A. R., Prodjosoewojo, S., Sofiatin, Y., Khrisna, C. V., Sari, R. M., Setyaningsih, L., Surachman, F., Bachtiar, N. S., Sukandar, H., Megantara, I., Murad, C., Pangesti, K. N. A., Setiawaty, V., Sudigdoadi, S., Hu, Y., Gao, Q., & Kartasasmita, C. B. (2021). A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia. Vaccine, 39(44), 6520–6528. https://doi.org/10.1016/j.vaccine.2021.09.052

Chicago

Fadlyana, Eddy, Kusnandi Rusmil, Rodman Tarigan, Andri Reza Rahmadi, Susantina Prodjosoewojo, Yulia Sofiatin, Citra V. Khrisna, et al. 2021. “A Phase III, Observer-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18–59 Years: An Interim Analysis in Indonesia.” Vaccine 39 (44): 6520–28. doi:10.1016/j.vaccine.2021.09.052.